BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19596875)

  • 21. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
    Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
    Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
    Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid versus vancomycin for skin and soft tissue infections.
    Yue J; Dong BR; Yang M; Chen X; Wu T; Liu GJ
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008056. PubMed ID: 23846850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infective endocarditis and glycopeptides.
    Pittet D; Harding I
    J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson R
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of teicoplanin in the treatment of febrile neutropenia.
    Menichetti F
    J Chemother; 2000 Nov; 12 Suppl 5():34-9. PubMed ID: 11131962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the safety profile of teicoplanin.
    Davey PG; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():69-73. PubMed ID: 1829079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
    Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
    J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design.
    Vardakas KZ; Mavros MN; Roussos N; Falagas ME
    Mayo Clin Proc; 2012 Apr; 87(4):349-63. PubMed ID: 22469348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
    Chow AW; Jewesson PJ; Kureishi A; Phillips GL
    Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Yahav D; Lador A; Paul M; Leibovici L
    J Antimicrob Chemother; 2011 Sep; 66(9):1963-71. PubMed ID: 21685488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer.
    Rolston KV; Nguyen H; Amos G; Elting L; Fainstein V; Bodey GP
    J Infect Dis; 1994 Feb; 169(2):350-5. PubMed ID: 8106768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
    Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin-induced neutropenia resolves after substitution with teicoplanin.
    Sanche SE; Dust WN; Shevchuk YM
    Clin Infect Dis; 2000 Sep; 31(3):824-5. PubMed ID: 11017842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
    Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
    Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters.
    Smith SR; Cheesbrough J; Spearing R; Davies JM
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1193-7. PubMed ID: 2529814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.